EKR Therapeutics Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$150M
EKR Therapeutics General Information
Description
Developer of prescription products intended to serve the needs of the acute-care hospital setting. The company's products support the life of cancer patients, offer short-term treatment of hypertension and management of various AMI related conditions, enabling patients to get access to preferred treatment at a cost effective manner.
Contact Information
Website
www.ekrtx.comCorporate Office
- Third Floor
- Bedminster Township
- NJ 07921
- United States
Corporate Office
- Third Floor
- Bedminster Township
- NJ 07921
- United States
EKR Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 27-Jun-2012 | $150M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series D) | 10-Mar-2008 | Completed | Startup | |||
| 3. Later Stage VC (Series C) | 22-Aug-2007 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 15-Nov-2006 | $7.33M | $7.33M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 27-Jun-2006 | Completed | Startup |
EKR Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EKR Therapeutics Patents
EKR Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2009086166-A1 | Room temperature stable, lyophilized natriuretic peptide formulations | Inactive | 19-Dec-2007 | ||
| US-20070249689-A1 | Containing nicardipine; cardiovascular disorders; storage stability | Active | 18-Apr-2006 | ||
| US-7612102-B2 | Containing nicardipine; cardiovascular disorders; storage stability | Active | 18-Apr-2006 | ||
| AU-2007237903-A1 | Pre-mixed, ready-to-use iv bolus compositions and methods of use | Inactive | 18-Apr-2006 | ||
| EP-2012788-A2 | Pre-mixed, ready-to-use iv bolus compositions and methods of use | Inactive | 18-Apr-2006 | A61K47/02 |
EKR Therapeutics Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Canterbury Capital (South Carolina) | Venture Capital | Minority | ||
| Commerce Health Ventures | Venture Capital | Minority | ||
| ESP Equity Partners | PE/Buyout | Minority | ||
| LLR Partners | Growth/Expansion | Minority | ||
| MPM BioImpact | Venture Capital | Minority |
EKR Therapeutics FAQs
-
When was EKR Therapeutics founded?
EKR Therapeutics was founded in 2006.
-
Where is EKR Therapeutics headquartered?
EKR Therapeutics is headquartered in NJ.
-
What industry is EKR Therapeutics in?
EKR Therapeutics’s primary industry is Pharmaceuticals.
-
Is EKR Therapeutics a private or public company?
EKR Therapeutics is a Private company.
-
What is the current valuation of EKR Therapeutics?
The current valuation of EKR Therapeutics is .
-
What is EKR Therapeutics’s current revenue?
The current revenue for EKR Therapeutics is .
-
How much funding has EKR Therapeutics raised over time?
EKR Therapeutics has raised $166M.
-
Who are EKR Therapeutics’s investors?
Canterbury Capital (South Carolina), Commerce Health Ventures, ESP Equity Partners, LLR Partners, and MPM BioImpact are 5 of 10 investors who have invested in EKR Therapeutics.
-
When was EKR Therapeutics acquired?
EKR Therapeutics was acquired on 27-Jun-2012.
-
Who acquired EKR Therapeutics?
EKR Therapeutics was acquired by Chiesi USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
